EDINBURGH, Scotland, Jan. 13, 2025 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP), a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that CEO Bryan Kobel will be presenting a corporate overview at the upcoming Sequire Investor Summit 2025. The conference is scheduled for January 21-23, 2025, at the Condado Vanderbilt Hotel in San Juan, Puerto Rico. For more informati ...

EDINBURGH, Scotland, Jan. 6, 2025 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that its American Depository Shares (ADSs) has continued trading on the Nasdaq Global Select Market (Nasdaq) under the ticker symbol 'TCBP'. There has been no halt in trading and shares are expected to continue trading unabated. This pres ...

EDINBURGH, Scotland, Dec. 30, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that shareholders have formally approved the recently announced 25% stock dividend. Today, TC BioPharm declared that last week's proposed special stock dividend was formally approved at today's General Meeting of the Company. The special ...

Clinical Trial Progress - The ACHIEVE UK clinical trial is a phase II study evaluating the efficacy of TCB008 in patients with AML or MDS/AML, focusing on refractory or relapsed disease [1] - Preliminary safety data shows the 5mL dose of TCB008 is well tolerated with no drug-related Adverse Events, aligning with the safety profile [2] - 3 patients have completed the full-dose regimen in the ACHIEVE Phase 2b trial with no drug-related Adverse Events observed [5] - 10 patients have received their first dose, 9 their second dose, 4 their third dose, and 3 their fourth and final dose [9] - 9 out of 10 recruited patients are in Cohort A (relapsed/refractory), while 1 patient is in Cohort B (remission with residual disease) [9] - Recruitment for the ACHIEVE trial has been successful, with over half of Cohort A patients recruited in less than 5 months [10] Company Overview - TC BioPharm is a clinical-stage biopharmaceutical company developing gamma-delta T cell therapies for cancer treatment [3][11] - The company is the first to conduct phase II/pivotal clinical studies in oncology using gamma-delta T cell therapies [3] - TC BioPharm is conducting two investigator-initiated clinical trials, including a Phase 2b/3 pivotal trial for acute myeloid leukemia using its proprietary CryoTC technology [3] Future Plans and Expectations - The company plans to recruit 14 patients initially into Cohort A and B, with an additional 10 patients per cohort after confirming study endpoints, totaling 48 patients [9] - The immediate clinical focus is on high recruitment for Cohort B in 2025 and completing data review for Cohort A [6] - The CEO highlighted the potential for an expedited review due to the patients' stage and disease expression, with minimal residual disease representing a high opportunity for TCB008 [6]

EDINBURGH, Scotland, Dec. 18, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that its Board of Directors has approved a special dividend to its shareholders of 0.25 American Depositary Shares ("ADSs") for every 1 ADS held by shareholders, pending shareholder approval. The Company intends to hold a general meeting ...

On Wednesday, TC BioPharm (Holdings) PLC TCBP announced that its Board of Directors approved a special dividend of 0.25 American Depositary Shares for every 1 ADS held by shareholders, pending shareholder approval.The company intends to hold a general meeting of shareholders on Monday, December 30.The dividend is expected to be declared on December 30, 2024, and payable to shareholders who own the company's stock at the close of trading on January 02, 2025."We are extremely pleased to announce this special ...

Positive safety data, allowing for exploration of higher TCB008 doses 4 UK-based clinical sites recruiting patients, with a further 2 sites expected in H1 2025EDINBURGH, Scotland, Dec. 4, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced an update on the progression of the ACHIEVE UK Trial.As of this week, over hal ...

Exhibit 99.1 Unless we state otherwise or the context otherwise requires, the terms "TC Biopharm,", "TCB", "we," "us," "our" and the "Company" refer to TC Biopharm (Holdings) plc. SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Report contains forward-looking statements that involve risks and uncertainties. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. All statements other than ...

EDINBURGH, Scotland, Oct. 30, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP), a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today provides an update to its shareholders and highlighted the Company's operational achievements thus far in 2024. "The Company has made tremendous strides during the current year and bolstered its standing as a leading clinical-stage biopharmaceuti ...

TC BioPharm remains compliant with all Nasdaq listing requirements and will continue trading on the exchangeEDINBURGH, Scotland, Oct. 25, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP), a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today refuted a false claim made earlier this week on social media, stating there is absolutely no way the company is in any danger of being de ...